Vista Therapeutics Business

Vista is now approaching markets that do and do not require FDA approval. Biomedical research, pre-clinical and clinical drug safety and efficacy, and point-of-care patient monitoring are among Vista's priorities. The current opportunity for non-FDA-regulated products is approximately $6 billion world-wide and includes drug safety and efficacy testing, clinical trials, and clinical research. For FDA-regulated clinical applications, the market approaches $23 billion, including equipment and disposables for ICU patients and doctors' offices. Vista is first reaching out to pharmaceutical companies working on ephemeral conditions such as seizure. stroke, blunt trauma, sepsis, severe allergic reactions, and sleep disorders.

Through care, hard work, and good fortune, Vista has assembled a suite of critical assets. Briefly, Vista has aligned: a) A team of world-class experts in medicine, biotechnology, nanotechnology, engineering, chemistry, and informatics; b) Broad, controlling, issued patents in key technology areas; c) A collaboration in essential fields with Harvard University; d) Extensive experience in cutting-edge biotechnology business development; and e) A working relationship with pharmaceutical companies, doctors, and medical researchers. Vista is in the process of leveraging these assets as it deploys its NanoBioSensor.

Nanotechnology will profoundly affect multiple facets of drug discovery, drug safety assessment, and the diagnosis and treatment of disease. An important near-term contribution of nanotechnology to biomedicine will be sensitive biomarker sensors. The current biomarker market is approximately $5.6 billion and is growing by 18% per year. Vista Therapeutics has recently commercialized a nanowire-based biosensor (our NanoBioSensor™) that offers real-time, continuous, label-free monitoring of multiple biomarkers, simultaneously at femtomolar concentrations.

Vista is headquartered in Santa Fe, New Mexico. (It may seem surprising, but according to Lux Research, New Mexico ranks fifth, with Massachusetts first, for nanotechnology and microsystems research.) Vista's Santa Fe facility includes its business office as well as its laboratory. Vista also collaborates with other organizations, including Harvard University and the University of New Mexico Medical School, where Vista has access to research, manufacturing, and clinical capabilities on an as-needed basis. Vista's products are manufactured at the Santa Fe facility and at high-tech engineering firms around the country.